EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist

David P Nichols, Sarah J Morgan, Michelle Skalland, Anh T Vo, Jill M Van Dalfsen, Sachinkumar Bp Singh, Wendy Ni, Lucas R Hoffman, Kailee McGeer, Sonya L Heltshe, John P Clancy, Steven M Rowe und 3 weitere

Journal of Clinical Investigation · 15.05.2023 · 133 (10)

DOI: 10.1172/jci167957 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Clinical Investigation, online erschienen am 15.05.2023. Verfasst von David P Nichols und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and. Hauptthemen laut MEDLINE: Cystic Fibrosis, Pneumonia. Die Arbeit wurde bisher 238-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, Cystic Fibrosis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisPneumoniaHumansCystic Fibrosis Transmembrane Conductance RegulatorSputumProspective StudiesBacteriaBenzodioxolesLungMutation

Stichwörter der Autor:innen

Bacterial infectionsMicrobiologyPulmonology

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorBenzodioxolesCFTR protein, human

Autor:innen und Institutionen

  • Department of Pediatrics and.
  • Departments of Microbiology and Medicine, University of Washington, Seattle, Washington, USA.
  • Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, Washington, USA.
  • Department of Medicine, University of Iowa, Iowa City, Iowa, USA.
  • Department of Medicine, University of Alabama, Birmingham, Alabama, USA.
  • Departments of Pathology and Laboratory Medicine, Medicine, and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • Cystic Fibrosis Foundation
  • NIH Office of the Director

Zitieren

APA

Nichols, D. P., Morgan, S. J., Skalland, M., Vo, A. T., Van Dalfsen, J. M., Singh, S. B., Ni, W., Hoffman, L. R., McGeer, K., Heltshe, S. L., Clancy, J. P., Rowe, S. M., Jorth, P., Singh, P. K., & PROMISE-Micro Study Group (2023). Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist. Journal of Clinical Investigation, 133(10). https://doi.org/10.1172/jci167957

Vancouver

Nichols DP, Morgan SJ, Skalland M, Vo AT, Van Dalfsen JM, Singh SB, et al. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist. Journal of Clinical Investigation. 2023;133(10). doi:10.1172/jci167957

BibTeX
@article{Nichols2023,
  author = {Nichols, David P and Morgan, Sarah J and Skalland, Michelle and Vo, Anh T and Van Dalfsen, Jill M and Singh, Sachinkumar Bp and Ni, Wendy and Hoffman, Lucas R and McGeer, Kailee and Heltshe, Sonya L and Clancy, John P and Rowe, Steven M and Jorth, Peter and Singh, Pradeep K and PROMISE-Micro Study Group, PROMISE-Micro Study Group},
  title = {Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist},
  journal = {Journal of Clinical Investigation},
  year = {2023},
  volume = {133},
  number = {10},
  doi = {10.1172/jci167957}
}
Kostenlos starten →